Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

US6313119A · kind A · utility

Assignees

• Adventis Pharma Deutschland GmbH · DE
• Genentech, Inc. · US

Inventors

• Anuschirwan Peyman · Kelkheim, DE
• David William Will · Schwalbach, DE
• Jochen Knolle · Kriftel, DE
• Karlheinz Scheunemann · Liederbach, DE
• Denis Carniato · Marcoussis, FR
• Jean-Francois Gourvest · Claye-Souilly, FR
• Thomas Gadek · Oakland, US
• Robert McDowell · San Francisco, US
• Sarah C. Bodary · San Francisco, US
• Robert Andrew Cuthbertson · Elmore, AU

Key dates

• Filing date: May 5, 2000
• Grant date: Nov 6, 2001
• Expiry date: May 5, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D239/16
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.